Trial intelligence / Profile preview

Phase II Trial of Lazertinib in EGFR-mutant Metastatic NSCLC with Brain Metastases After EGFR TKI Failure

KCT0006207Phase 2Completed

Sponsor

Korean Cancer Study Group

Start

Jun 2021

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1